Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) Shares Sold by Citigroup Inc.

Citigroup Inc. trimmed its position in Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) by 16.2% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 133,051 shares of the company’s stock after selling 25,720 shares during the quarter. Citigroup Inc. owned approximately 0.08% of Lineage Cell Therapeutics worth $157,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also modified their holdings of the company. Price T Rowe Associates Inc. MD grew its position in shares of Lineage Cell Therapeutics by 18.5% in the 2nd quarter. Price T Rowe Associates Inc. MD now owns 72,400 shares of the company’s stock valued at $114,000 after buying an additional 11,309 shares during the last quarter. Barclays PLC grew its position in shares of Lineage Cell Therapeutics by 87.3% in the 2nd quarter. Barclays PLC now owns 25,905 shares of the company’s stock valued at $36,000 after buying an additional 12,075 shares during the last quarter. Geode Capital Management LLC grew its position in shares of Lineage Cell Therapeutics by 1.1% in the 4th quarter. Geode Capital Management LLC now owns 1,264,409 shares of the company’s stock valued at $1,479,000 after buying an additional 13,253 shares during the last quarter. HighTower Advisors LLC grew its position in Lineage Cell Therapeutics by 46.9% during the 1st quarter. HighTower Advisors LLC now owns 50,116 shares of the company’s stock worth $75,000 after purchasing an additional 16,000 shares during the last quarter. Finally, Wealth Architects LLC purchased a new position in Lineage Cell Therapeutics during the 1st quarter worth $25,000. 62.47% of the stock is currently owned by institutional investors and hedge funds.

Lineage Cell Therapeutics Stock Up 5.7 %

LCTX stock opened at $1.48 on Friday. Lineage Cell Therapeutics, Inc. has a one year low of $0.84 and a one year high of $1.61. The firm has a market capitalization of $279.02 million, a PE ratio of -11.38 and a beta of 1.27.

Wall Street Analyst Weigh In

Several research analysts have issued reports on LCTX shares. Cantor Fitzgerald reissued an “overweight” rating and set a $6.00 price objective on shares of Lineage Cell Therapeutics in a research report on Monday, February 5th. HC Wainwright reissued a “buy” rating and set a $7.00 price objective on shares of Lineage Cell Therapeutics in a research report on Tuesday, February 13th.

Insider Transactions at Lineage Cell Therapeutics

In related news, Director Broadwood Partners, L.P. acquired 6,730,770 shares of Lineage Cell Therapeutics stock in a transaction that occurred on Tuesday, February 6th. The stock was purchased at an average price of $1.04 per share, for a total transaction of $7,000,000.80. Following the completion of the purchase, the director now directly owns 41,666,255 shares of the company’s stock, valued at $43,332,905.20. The purchase was disclosed in a document filed with the SEC, which is available through the SEC website. In related news, Director Broadwood Partners, L.P. acquired 6,730,770 shares of Lineage Cell Therapeutics stock in a transaction that occurred on Tuesday, February 6th. The stock was purchased at an average price of $1.04 per share, for a total transaction of $7,000,000.80. Following the completion of the purchase, the director now directly owns 41,666,255 shares of the company’s stock, valued at $43,332,905.20. The purchase was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Don M. Bailey acquired 96,155 shares of Lineage Cell Therapeutics stock in a transaction that occurred on Thursday, February 8th. The stock was bought at an average price of $1.04 per share, with a total value of $100,001.20. Following the purchase, the director now directly owns 158,801 shares of the company’s stock, valued at $165,153.04. The disclosure for this purchase can be found here. Company insiders own 28.10% of the company’s stock.

Lineage Cell Therapeutics Company Profile

Lineage Cell Therapeutics, Inc, a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer.